Zafirlukast (cas 107753-78-6) attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM)
-
Add time:08/17/2019 Source:sciencedirect.com
Zafirlukast (cas 107753-78-6), a leukotriene receptor antagonist, has been shown to exert a wide range of effects including anti-asthmatic, anti-inflammatory and oral anti-bacterial. Osteoarthritis is one of the most prevalent age-related public health burdens in the modern world. In the present study, we applied zafirlukast in the treatment of human primary chondrocytes and found that it exerts potent anti-osteoarthritic effects. Zafirlukast inhibited AGEs-induced degradation of the articular extracellular matrix by suppressing expression of MMPs, ADAMTS, NOX-4, generation of ROS, and activation of NF-κB via the IκBα/JNK/AP-1 pathway through targeted inhibition of CysLTR1. These findings suggest that zafirlukast possesses a protective effect against AGEs- induced damage and dysfunction in human chondrocytes.
We also recommend Trading Suppliers and Manufacturers of Zafirlukast (cas 107753-78-6). Pls Click Website Link as below: cas 107753-78-6 suppliers
Prev:Cysteinyl leukotriene receptor type 1 (CysLT1R) antagonist Zafirlukast (cas 107753-78-6) protects against TNF-α-induced endothelial inflammation
Next:Research paperBreathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor) - 【Back】【Close 】【Print】【Add to favorite 】